Skip to main content
. 2014 Sep 18;5(2):459–469. doi: 10.1007/s13300-014-0082-y

Table 1.

Demography and baseline characteristics (ITT population)

Mean ± SD or n (%) Vilda 50 mg bid + metformin Glim 2 mg/day + metformin Glim 6 mg/day +  metformin Glim “other” + metformin Glim “overall” + metformin
N a 1,539 417 589 514 1,520
Age (years) 57.5 ± 9.1 58.9 ± 9.2 56.3 ± 9.3 57.7 ± 9.1 57.5 ± 9.2
Sex
 Male 815 (53.0) 222 (53.2) 315 (53.5) 278 (54.1) 815 (53.6)
 Female 724 (47.0) 195 (46.8) 274 (46.5) 236 (45.9) 705 (46.4)
Race
 Caucasian 1,343 (87.3) 380 (91.1) 482 (81.8) 449 (87.4) 1,311 (86.3)
 Black 18 (1.2) 6 (1.4) 6 (1.0) 7 (1.4) 19 (1.3)
 Asian 43 (2.7) 9 (2.2) 13 (2.2) 22 (4.3) 44 (2.9)
 Hispanic/Latino 128 (8.3) 20 (4.8) 79 (13.4) 32 (6.2) 131 (8.6)
 All other 7 (0.5) 2 (0.5) 9 (1.5) 4 (0.8) 15 (1.0)
HbA1c (%) 7.3 ± 0.6 7.0 ± 0.5 7.5 ± 0.7 7.3 ± 0.6 7.3 ± 0.7
FPG (mmol/L) 9.1 ± 2.2 8.2 ± 1.6 9.9 ± 2.4 9.1 ± 2.1 9.2 ± 2.2
BMI (kg/m2) 31.9 ± 5.3 31.0 ± 5.2 32.4 ± 5.3 31.6 ± 5.2 31.7 ± 5.3
Duration of T2DM (years) 5.6 ± 5.1 5.3 ± 4.7 5.9 ± 5.0 5.8 ± 5.4 5.7 ± 5.1
Metformin use
 Duration (years) 3.0 ± 2.8 2.8 ± 2.8 3.0 ± 2.8 3.1 ± 3.1 3.0 ± 2.9
 Dose (mg/day) 1,899 ± 411 1,853 ± 394 1,902 ± 407 1,900 ± 421 1,888 ± 409
GFR (MDRD) (mL/min/1.73 m2)
 Normal (>80) 1,050 (68.2) 272 (65.2) 432 (73.3) 330 (64.2) 1,034 (68.0)
 Mild (≥50 to ≤80) 474 (30.8) 142 (34.1) 153 (26.0) 181 (35.2) 476 (31.3)
 Moderate (≥30 to <50) 13 (0.8) 3 (0.7) 4 (0.7) 3 (0.6) 10 (0.7)
 Severe (<30) 1 (0.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
 Missing 1 (0.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)

BMI body mass index, FPG fasting plasma glucose, Glim glimepiride, GFR glomerular filtration rate, HbA 1c glycated hemoglobin, MDRD modification of diet in renal disease, T2DM type 2 diabetes mellitus, Vilda vildagliptin

a N (BMI) = 1,534 (Vilda 50 mg bid), 414 (Glim 2 mg/day), 588 (Glim 6 mg/day), 511 (Glim ‘other’) and 1,513 (Glim ‘overall’); N (FPG) = 1,536 (Vilda 50 mg bid), 417 (Glim 2 mg/day), 588 (Glim 6 mg/day), 514 (Glim ‘other’) and 1,519 (Glim ‘overall’)